[Lotus]

So, Lotus, this might be the wrong place to put this, but it is a topical program thread: is it or is it not a good idea to do topical E2? I feel like I was told, by either you or other people, that topical E2 would desensitize receptors and/or aggravate cancer risk. What's the deal there?
Hugs,
Aria<3

Hi Aria, I moved your question to the appropriate thread. What I'm gonna explain next is a major discovery for discussion. Now, the notion that my posts are too complex comes with me understanding what science can do in relation to growing breasts. One can't pull something out their ass and claim it's fact about growing breasts… laughable… science will always be involved in new discoveries. Taming the science down is understandable, I don't need an interpreter to speak on behalf though, simply ask me for help with whatever meaning. Btw, to all, I do research because I enjoy it, and benefit from it, and hopefully you do too. It's not my “JOB”. 

I'm able (with confidence) to say that lipogenesis of breast tissue fights against breast cancer. I've been pushing around the idea of using PPAR (peroxisome proliferator-activated receptor) inhibitor I described in the “Topical Protocol” as Red Clover (RC) initiates lipogenesis. If you read the earlier posts in this thread you find additional information on the Topical benefit of estradiol.

lipogenesis is the conversion of fatty acids and glycerol into fats, or a metabolic process through which acetyl-CoA is converted to triglyceride for storage in fat.[1]
wiki. 

Here's the bullet points 
Mechanisms of nutritional and hormonal regulation of lipogenesis
https://pubmed.ncbi.nlm.nih.gov/11306547/

PARP Inhibitor
New partners in the therapy of cancer and inflammatory diseases

With three PARP inhibitors approved for use against ovarian cancer, however, it is an exciting time for the evaluation of combining PARP inhibition with conventional treatments, immunotherapy, or antiangiogenesis treatments for the treatment of genetically unstable and difficult-to-treat, aggressive cancers.
https://www.sciencedirect.com/topics/medicine-and-dentistry/parp-inhibitor

Topical Estradiol enhances the stimulatory effect of insulin-like growth factor-I (IGF-I) on mammary development and growth hormone-induced IGF-I messenger ribonucleic acid
https://pubmed.ncbi.nlm.nih.gov/7867584/

E2 significantly enhanced the effects of IGF-I on mammary development. Plus, E2 treatment improves collagen synthesis by making new collagen.

Topical application of E2 stimulates insulin-like growth factor receptors and increases the production of insulin-like growth factors from fibroblasts (Ashcroft et al., 1997), which in turn induces lipogenesis.

More to follow later.